Sorry, you need to enable JavaScript to visit this website.
Skip to main content

KAPRUVIA® IS DELIVERED AS A SIMPLE IV BOLUS AT THE END OF HD 1

KAPRUVIA® can be administered as part of your patient’s in-centre HD routine:*1

KAPRUVIA® is administered three times per week at the end of HD treatment†1

The recommended dose of KAPRUVIA® is 0.5 μg/kg dry body weight1

KAPRUVIA® is administered as a simple IV bolus injection into the venous line of the dialysis circuit during rinse-back or after rinse-back‡1

  • When given after rinse back, at least 10 mL of sodium chloride
    9 mg/mL (0.9%) solution rinse-back volume should be
    administered after injection of KAPRUVIA®
  • If the dose is given during rinse back, no additional sodium
    chloride 9 mg/mL (0.9%) solution is needed to flush the line

KAPRUVIA® INJECTION VOLUMES1

Target Dry Body Weight Range (kg) Injection Volume (mL)
40 – 44 0.4
45 – 54 0.5
55 – 64 0.6
65 – 74 0.7
75 – 84 0.8
85 – 94 0.9
95 – 104 1.0
105 – 114 1.1
115 – 124 1.2
125 – 134 1.3
135 – 144 1.4
145 – 154 1.5
155 – 164 1.6
165 – 174 1.7
175 – 184 1.8
185 – 194 1.9
≥195 2.0

The total dose volume (mL) required from the vial should be
calculated as: 0.01 × dry body weight (kg),
rounded to the nearest
tenth (0.1 mL).1

Dosing is the same for elderly patients aged ≥65 years as adult
patients.§1

No dose adjustment is required for patients with mild or moderate
hepatic impairment.¶1

warning
  • KAPRUVIA® should not be diluted or mixed with other medicinal products
  • Vials are for single-use only, discard any unused product
  • KAPRUVIA® should be a clear, colourless solution, free from particles. Inspect for any particulate matter or discolouration before administration

CKD, chronic kidney disease; CKD-associated Pruritus, chronic kidney disease-associated pruritus; HD, haemodialysis; IV, intravenous.

*KAPRUVIA® administration should be restricted for in-centre HD only and is intended for use by HCPs experienced in the diagnosis and treatment of moderate-to-severe CKD-associated Pruritus. Causes of pruritus other than CKD should be excluded before initiating treatment with KAPRUVIA®.
If a regular HD treatment is missed KAPRUVIA® should be administered at the next HD treatment. For HD treatments less than 1 hour, administration of KAPRUVIA® should be withheld until the next haemodialysis session. If a 4th HD treatment is performed in a week KAPRUVIA® should be administered at the end of the HD per the recommended dose. No more than 4 doses per week should be administered even if the number of HD treatments administered in a week exceeds 4. A 4th dose of KAPRUVIA® is unlikely to lead to accumulation of KAPRUVIA® that would be of concern for safety, as the majority of remaining KAPRUVIA® from the previous treatment
will be cleared by HD. However, safety and efficacy of a 4th dose has not been fully established due to insufficient data.

KAPRUVIA® is removed by the dialyzer membrane and must be administered after blood is no longer circulating through the dialyzer.
§The safety and efficacy of KAPRUVIA® in children aged 0-17 years has not yet been established. No data are available.
KAPRUVIA® has not been studied in subjects with severe hepatic impairment (National Cancer Institute Organ Dysfunction Working
Group) and is therefore not recommended for use in this patient population.

Reference:

1. KAPRUVIA® Summary of Product Characteristics, 2022.

Disclaimer: This is an international website for Kapruvia and is intended for health care professionals outside the US. If you are a US resident, please go to korsuva.com/hcp. The information on this site is not country-specific and may contain information that may not be relevant in the country in which you are located.